A Note on the Calculation of Recovery for Factor VIII Infusions

Thromb Haemost 1993; 69(01): 087
DOI: 10.1055/s-0038-1651555

Letter to the Editor

Schattauer GmbH Stuttgart

Authors

Martin L Lee

Baxter Healthcare Corporation, Hyland Division, 550 N. Brand Boulevard Glendale, California 91203, U.S.A.
Edward D Gomperts

Baxter Healthcare Corporation, Hyland Division, 550 N. Brand Boulevard Glendale, California 91203, U.S.A.
Henry S Kingdon

Baxter Healthcare Corporation, Hyland Division, 550 N. Brand Boulevard Glendale, California 91203, U.S.A.

References
1 Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemostas 1991; 66: 384-386
2 Allain JP, Verroust F, Soulier JP. In vitro and in vivo characterization of factor VIII preparations. Vox Sanguinis 1980; 38: 68-80
3 Hellstern P, Kiehl R, Miyashita C, Schwerdt H, von Blohn G, Köhler M, Büttner M, Wenzel E. Factor VIII: C (FVIII: C) recovery and halflife after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia – comparison of one-stage assay, two-stage assay and a chromogenic substrate assay. Thromb Haemostas 1986; 56: 353-359
4 Brettler DB, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan JL. Factor VIII: C concentrate purified from plasma using monoclonal antibodies: human studies. Blood 1989; 73: 1859-1863
5 Lee ML, White G, Morfini M, Courter S, Kingdon H. Comparison of recombinant and monoclonally-purified AHF pharmacokinetics: The use of a two-phase linear regression model. Blood 1989; 74 (Suppl. 01) 393a
6 Shanbrom E, Thelin GM. Experimental prophylaxis of severe hemophilia with a factor VIII concentrate. JAMA 1969; 208: 1853-1856
7 Abildgaard CF, Simone JV, Corrigan JJ. et al. Treatment of hemophilia with glycine-precipitated factor VIII. N Engl J Med 1966; 275: 471-475